ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2292

Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?

Dina Zucchi1, Giancarlo Cascarano2, Antonio Collesei3, Elena Elefante2, Francesca Monacci4, Chiara Ietto4, Linda Carli2, Sabrina Gori2, Valentina Gelsi4, Chiara Tani2 and Marta Mosca2, 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy, 2Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 3Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy, 4Department of Clinical and Experimental Medicine, Division of Obstetrics and Gynecology, University of Pisa, Pisa, Italy

Meeting: ACR Convergence 2023

Keywords: pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) patients are at risk of disease flare during pregnancy; risk stratification is crucial for personalized treatment and monitoring. Our hypothesis is that a machine learning (ML) approach could improve the flare prediction accuracy, enabling early identification of high-risk pregnancies. In this study, we aimed to build a ML model capable of predicting disease flares based on clinical and serological data obtained early in pregnancy.

Methods: 105 pregnancies in 84 SLE patients were prospectively followed at 4-week intervals during pregnancy and puerperium. At the first visit during pregnancy, demographic and clinical data, treatments as well as disease state at the last visit before pregnancy were gathered. At each visit, disease activity was assessed by means of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Physician Global Assessment (PhGA). Disease state was defined according to the LLDAS and DORIS definitions. Flares were defined as the emergence or worsening of symptoms requiring therapeutic adjustments or hospitalization. Classical inferential statistics by means of multivariate logistic regression were paralleled by a ML approach to predict the risk of flare based on baseline variables. After missing data imputation and variable filtering, the dataset was subdivided into training and test set, with 70-30% split. A Generalized Linear Model (GLM) with repeated cross-validation was then fitted on the training set, with the aim of predicting “the emergence of flares”.

Results: 25 flares occurred among the 105 pregnancies examined (26.25%). Patients’ demographic and clinical data are shown in Table 1. At univariate analysis, the variables significantly associated with flare were LLDAS without remission at last evaluation (p=0.045) and at first visit during pregnancy (p< 0.01), shorter disease duration (p< 0.01), anti-dsDNA positivity (p=0.03), higher SLEDAI (p=0.02) and higher PGA (p=0.02) at first visit during pregnancy. Remission status at both last (p< 0.01) and first visit during pregnancy (p< 0.01) and planned pregnancy (p< 0.01) were protective. In the multivariate analysis, planned pregnancy and disease duration remained significant (OR 0.84 CI 0.72 to 0.98 p=0.02 and OR 0.18 CI 0.45 to 0.78 p=0.02, respectively). The ML model achieves a high accuracy of 96.3% in predicting the target, unlocking the possibility to enact prevention measures on fragile subjects. Additionally, the model identifies key parameters for patient information collection. The model’s optimization gives different weights and statistical importance to each variable (Figure 1), confirming the importance of the two previously recognized predictors, including renal involvement, among others.

Conclusion: The constructed ML model has demonstrated remarkable accuracy in identifying flare occurrences during pregnancy based on baseline data. It is worth noting that both the statistical analysis and the ML model emphasized parameters such as proper pregnancy planning and disease duration at conception as the most influential in predicting the likelihood of a flare during gestation.

Supporting image 1

Supporting image 2


Disclosures: D. Zucchi: None; G. Cascarano: None; A. Collesei: None; E. Elefante: None; F. Monacci: None; C. Ietto: None; L. Carli: None; S. Gori: None; V. Gelsi: None; C. Tani: None; M. Mosca: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, GlaxoSmithKlein(GSK), 2, Otsuka, 2, UCB, 2.

To cite this abstract in AMA style:

Zucchi D, Cascarano G, Collesei A, Elefante E, Monacci F, Ietto C, Carli L, Gori S, Gelsi V, Tani C, Mosca M. Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/is-machine-learning-useful-to-predict-flare-during-pregnancy-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-machine-learning-useful-to-predict-flare-during-pregnancy-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology